We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
J&JPRD Joins the Simcyp Consortium and Licenses the Simcyp Simulator
News

J&JPRD Joins the Simcyp Consortium and Licenses the Simcyp Simulator

J&JPRD Joins the Simcyp Consortium and Licenses the Simcyp Simulator
News

J&JPRD Joins the Simcyp Consortium and Licenses the Simcyp Simulator

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "J&JPRD Joins the Simcyp Consortium and Licenses the Simcyp Simulator"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Simcyp has announced that Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) has joined the Simcyp Consortium and is now providing access to the Simcyp Population-based ADME Simulator and Paediatric module to its global network of research & development teams.

Prior to taking up the three server licenses, eleven J&JPRD ADME scientists from multiple sites undertook a rigorous evaluation of the Simulator to ensure that it would fulfill their requirements for the future. The contract between Simcyp and J&JPRD, a division of Janssen Pharmaceutica NV, will run for three years.

The Simcyp Simulator is an advanced platform for the modeling and simulation of drug absorption and disposition in virtual populations, including children. This enables individuals at extreme risk from adverse reaction to be identified, and unnecessary drug exposure to human volunteers and animals to be minimized.

The limitations of candidate compounds, including potential drug-drug interactions, can be assessed and managed prior to human studies, allowing better focus of drug development resources.

Professor Geoff Tucker, Chairman of Simcyp Limited, commented: “We are delighted that Johnson and Johnson, one of the world’s leading pharmaceutical companies, has joined the Simcyp Consortium. Following on from their thorough in-house evaluation of the Simulator, we anticipate that its further application will provide major benefits to them in their drug discovery and development programmes."

Advertisement